ALZHEIMER'S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING

FDA Approves Subcutaneous Leqembi for Alzheimer's

The FDA approved a subcutaneous version of Leqembi for weekly maintenance to treat Alzheimer's disease after the 18-month intravenous (IV) phase.

ALZHEIMER'S ASSOCIATION WELCOMES FDA ACTION APPROVING LEQEMBI WEEKLY SUBCUTANEOUS MAINTENANCE DOSING

CHICAGO, Aug. 29, 2025 /PRNewswire/ -- The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early Alzheimer's disease. With this approval, Leqembi IQLIK is the first…

Biogen wins approval of at-home version of Alzheimer's drug Leqembi

FDA approves at-home injection for Biogen and Eisai's Alzheimer's drug Leqembi. Read more here.

New Leqembi under-the-skin autoinjector approved for early...

The U.S. Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb), an under-the-skin autoinjector formulation for maintenance dosing in early Alzheimer’s disease. The approval, announced by co-developers Biogen and Eisai, applies to those who first receive at least 1.5 years of the intravenous version. The approval gives patients the option to continue infusions into a vein once every four weeks or start a weekly subcutaneo…

FDA Approves Lecanemab Subcutaneous Formulation as Maintenance Dose for Alzheimer Disease

FDA approves Leqembi's subcutaneous formulation, enhancing accessibility for Alzheimer's treatment and paving the way for future combination therapies.

FDA approves Eisai and Biogen’s Leqembi Iqlik BLA for early Alzheimer’s

This new dosing option enables patients with mild cognitive impairment or mild dementia to receive treatment at home, following an initial intravenous (IV) administration. Leqembi Iqlik, administered through The post FDA approves Eisai and Biogen’s Leqembi Iqlik BLA for early Alzheimer’s appeared first on Pharmaceutical Business review.